The Nano-Machinery of Cardiac Electrical Excitation
===================================================

For over a century, it has been recognized that cardiac myocytes come into close contact at the intercalated disk (ID), where adjacent cells are only nanometers apart. By the mid-20^th^ century, gap junctions (GJs) were identified as specialized structures within the ID, which afford electrochemical coupling between cells ([@B106]; [@B8]). The closest apposition between neighboring myocytes occurs within these GJs, with as little as 2 nm separating the cells. Despite this, GJs themselves do not constitute a functional nanodomain -- they afford direct cytosolic continuity between coupled cells, and since neither cytosolic compartment is a restricted environment, the effects unique to nanoscale compartments do not come into play. Thus, cardiac conduction, the cell-to-cell spread of electrical excitation through the heart, was thought a relatively simple process with cardiac voltage-gated sodium (Na^+^) channels (Na~V~1.5) affording excitability, and GJs providing cell-to-cell electrical coupling ([@B57]).

This electrotonic view of cardiac conduction allowed the formalism of cable theory to be applied to cardiac conduction, and adequately explained experimental observations for several decades ([@B57]). However, findings have accumulated, that are not well-explained by this model. Transgenic mice with reduced Cx43 expression displayed significant conduction slowing in some studies ([@B42]; [@B33]; [@B44]), but not in others ([@B83]; [@B123]; [@B118]; [@B9]; [@B24]; [@B125]; [@B113]). Likewise, GJ remodeling and reduced Cx43 expression correlated with arrhythmogenic conduction slowing in one pacing-induced canine heart failure model ([@B89]), but preceded it in another ([@B4]). Another discrepant finding stemmed from investigations of the electrophysiological impact of cardiac interstitial edema (fluid accumulation in the extracellular space): per the electrotonic model, an increase interstitial volume would lower extracellular resistance, and consequently, increase conduction velocity ([@B109]; [@B88]). However, experimental measurements in guinea pig ventricles revealed conduction slowing during to interstitial edema ([@B133], [@B131], [@B132]) and edema was linked to reversible conduction block in patients undergoing ablation for the treatment of atrial fibrillation (AF) ([@B7]). These findings prompted speculation that non-electrotonic mechanisms of intercellular communication may play a role in the heart.

Theoretical studies had long raised the possibility of an alternate mode of intercellular coupling ([@B86]; [@B110]; [@B59]; [@B111]; [@B23]; [@B82]). Dubbed ephaptic coupling, this mechanism envisions cells communicating via local extracellular electrochemical transients (ion accumulation/depletion). The aforementioned models suggest that a cardiac ephapse (a functional nanodomain capable of supporting ephaptic coupling) would require Na~V~1.5-rich membranes from neighboring cells, separated by a very narrow extracellular cleft (≤30 nm) ([@B127],[@B128]). Whereas channels located at the lateral sarcolemma would face a large bulk of extracellular fluid with a practically inexhaustible supply of ions, channels facing narrow extracellular clefts would have a limited supply of ions. In the latter case, ion channel activity could mount local extracellular electrochemical transients, in turn altering the local transmembrane potential. In this context, early results demonstrating that Na~V~1.5 channels are enriched at the ID ([@B72]; [@B87]) prompted speculation that functional nanodomains capable of supporting ephaptic coupling, i.e., ephapses, may exist within the ID. Until recently, the 250--350 nm resolution limit imposed on confocal microscopy by diffraction had precluded precise localization of Na~V~1.5 within the ID. However, this restriction was removed by the advent of super-resolution microscopy techniques with resolutions extending down to 20 nm. Work conducted by the Gourdie ([@B101]; [@B130], [@B131]; [@B126]) and Delmar ([@B3], [@B2]; [@B64]) labs using super-resolution techniques identified Na~V~1.5 enrichment within specific regions of the ID (**Figure [1](#F1){ref-type="fig"}**). One sub-population of ID-localized Na~V~1.5 was located at the perinexus, a specialized nanodomain located at the periphery of Cx43 GJs ([@B100]; [@B99]). A second localized to N-cadherin-rich plicate regions of the ID, where mechanical junctions are concentrated. Electron microscopy studies revealed disparate ultrastructural properties at these sites: within the perinexus, adjacent cell membranes were no more than 10--15 nm apart ([@B131]), whereas at N-cadherin-rich mechanical junctions, intermembrane spacing was as high as 60--75 nm ([@B65], [@B64]). The latter significantly exceeds the theoretically derived ≤ 30 nm intermembrane spacing limit for ephaptic coupling; however, the properties of the perinexus may enable it to function as an ephapse.
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Providing functional support for the ephaptic coupling hypothesis, the Poelzing and Gourdie groups demonstrated that acute interstitial edema selectively disrupted perinexal ultrastructure without altering other ID sites, and precipitated arrhythmogenic conduction slowing ([@B133], [@B131], [@B132]). Additionally, perinexal disruption increased the dependence of conduction on GJ coupling and vice versa, suggesting that both modes of intercellular coupling operate in tandem ([@B133]). Notably, in a setting of perinexal disruption, inhibition of channels enriched at perinexal sites -- Na~V~1.5, and inward-rectifier potassium channels (K~ir~2.1) -- resulted in anisotropic changes in conduction velocity, preferentially affecting transverse conduction ([@B131], [@B132]). In contrast, modulating ionic currents under normal conditions does not produce direction-specific impact. Keener and colleagues demonstrated that these experimental results could be predicted by a computational model incorporating both ephaptic and electrotonic coupling, but not by a purely electrotonic model ([@B68], [@B69]; [@B131], [@B132]). Recently, Hichri and colleagues provided experimental and *in silico* evidence that the behavior of ID-localized Na~V~1.5 is modulated by their clustering, location within the ID (relative to the bulk interstitium), and the trans-alignment of these clusters ([@B46]). In sum, these results illustrate macroscopic physiologic phenomena driven by the behavior of functional nanodomains, which can only be understood through knowledge of structure--function relationships at the nanodomain level.

In the larger context, the results highlighting the perinexus as a functional nanodomain involved in cardiac cell-to-cell communication pose the question: is the ID home to other functional nanodomains? The likelihood is high, given that the ID contains other sites enriched with Na~V~1.5 ([@B80]; [@B131]; [@B64]) and K~ir~2.1 ([@B80]; [@B132]; [@B91]) as well as other ion channel species such as ATP-sensitive K^+^ channels (K~ir~6.2) ([@B47]). Notably, extracellular sodium has been shown to strongly modulate K~ir~2.1 function ([@B51]), hinting at the potential for complex interrelationships between ion channel species within ID nanodomains. Thus, ID-localized ion channels clearly merit further investigation, with particular emphasis on their protein neighbors and local structural environment, both within the cell and without. In this regard, available observations on the composition and subcellular location of Na~V~1.5-containing macromolecular complexes hint at significant complexity. Na~V~1.5 has been demonstrated to associate with ankyrin-G ([@B74]), SAP97 ([@B87]; [@B40]), K~ir~2.1 and Kir2.2 ([@B80]; [@B76]; [@B91]), syntrophin and dystrophin ([@B87]), and CASK ([@B32]). Both ankyrin-G and SAP97 preferentially associate with ID-localized Na~V~1.5. However, loss of ankyrin-G reduced functional Na~V~1.5 expression ([@B74]) whereas loss of SAP97 did not ([@B40]). Similarly, Na~V~1.5 at the lateral sarcolemma associates with syntrophin, dystrophin, and CASK. Loss of dystrophin reduced Na~V~1.5 functional expression at this location ([@B87]). Conversely, loss of CASK increased Na~V~1.5 surface expression at the lateral sarcolemma ([@B32]). These intriguing findings suggest that we have much to learn about the organization and regulation of sodium channel-rich nanodomains, and the functional implications thereof.

Pathophysiology
---------------

Pathological alterations in Na~V~1.5 function are a well-established cause of cardiac arrhythmias ([@B134]; [@B108]). Likewise, GJ remodeling is widely recognized as a feature of multiple cardiac pathologies ([@B56]; [@B114]), and implicated as a contributor to arrhythmogenesis ([@B25]; [@B84]). While the arrhythmogenic impacts of functional loss of I~Na~ and GJ coupling have long been subjects of intense inquiry, we are only beginning to recognize the effects of nanoscale organization of Na~V~1.5 and Cx43, various scaffolding proteins associated with them, and changes in their ultrastructural environment. An interesting development in this context is the growing appreciation of the non-channel functions of Cx43 and their role in pathophysiology ([@B1]). Knockdown of Cx43 in mice was associated with concomitant reductions in Na~V~1.5 expression, and I~Na~ density ([@B52]) but not with alterations in adherens junctions or desmosomes ([@B43]). Proximity ligation assays indicate that the association between Cx43, and Na~V~1.5 is concentrated within the perinexus ([@B101]). This raises the possibility that the aforementioned loss of I~Na~ function may result from the loss of Cx43 to scaffold Na~V~1.5 within perinexal nanodomains, and thereby, preferentially impact these sites. Thus, nanopathy may underlie arrhythmias in the wide array of cardiac pathologies where Cx43 is remodeled ([@B4]; [@B28]; [@B30]; [@B21]). Along similar lines, missense mutations in the desmosomal protein plakophilin-2 were demonstrated to reduce N-cadherin-associated Na~V~1.5 density at the ID, reduce I~Na~, and result in a Brugada syndrome phenotype ([@B19]). Taken together, these results underscore the clinical relevance of understanding the molecular organization of functional nanodomains, and the specific role of nanopathy in disease.

In addition to direct alterations of Na~V~1.5 and/or its molecular partners, nanopathy could also result from pathological changes in nanodomain ultrastructure. In this context, the previously discussed effects of interstitial edema on the perinexal nanodomain take on interesting implications given the wide array of pathologies that are associated with both cardiac edema and arrhythmias ([@B77], [@B78]; [@B15]; [@B35]; [@B79]). Additionally, in long QT syndrome type 3 (LQT3; a disorder stemming from pathological gain of Na~V~1.5 function), the Poelzing group recently demonstrated that transient depletion of extracellular Na^+^ within perinexal nanodomains may mitigate risk of premature beats, and that perinexal widening may unmask the latent arrhythmia risk ([@B41]). More recently, they have demonstrated that wider perinexi associated with the occurrence of AF in human patients ([@B98]). While these are early days yet, these results collectively support the view that ultrastructural alterations within Na~V~1.5-rich nanodomains may be a key determinant of arrhythmia risk, and therefore, a potential target for antiarrhythmic therapy.

The Nano-Machinery of Cardiac Excitation-Contraction Coupling
=============================================================

Our understanding of excitation--contraction coupling (ECC) has followed a similar trajectory to the one outlined for the electrical excitation. Early studies first identified invaginations in the membrane called transverse (T)-tubules ([@B71]) and demonstrated that an activating current localized to those domains prompts contraction ([@B49], [@B50]). Subsequent work demonstrated that Ca^2+^ entry through the sarcolemma, via L-type Ca^2+^ channels (LTCC), results in calcium-induced calcium release from the sarcoplasmic reticulum (SR) via ryanodine receptor channels (RyR2) to couple electrical excitation with mechanical contraction ([@B34]). Examination of the structural underpinnings of cardiac ECC led to the identification of a restricted space dubbed the "fuzzy" dyadic space ([@B63]) where the sarcolemma and the terminal cisternae of the SR are separated by only ∼12 nm ([@B36]) (**Figure [1](#F1){ref-type="fig"}**). These results led to the realization that local protein function and electrochemical fluxes within nanodomains govern ECC rather than bulk effects across larger scales. Indeed, both systolic and diastolic Ca^2+^ concentrations in the dyadic cleft have been found to exceed that of the bulk cytosol ([@B27]; [@B92]), and differences in Na^+^ concentrations have been reported as well ([@B26]).

An early clue to the complexity of the dyadic nanodomain function came with the demonstration by Leblanc and Hume that Na^+^ influx may regulate Ca^2+^ release ([@B62]). Specifically, they provided evidence that Na^+^ influx during the action potential upstroke was linked with Ca^2+^ cycling through the action of the Na^+^--Ca^2+^ exchanger (NCX). Interestingly, a component of I~Na~ persists during the plateau phases, dubbed late I~Na~, and is tetrodotoxin (TTX) -- sensitive ([@B22]). Further investigation along these intriguing lines by the Bridge and Goldhaber groups suggested the involvement of neuronal Na^+^ channel (nNa~V~) isoforms ([@B119]). This findings are consistent with aforementioned structural results: (1) Na~V~1.5 localizes to the ID and the lateral sarcolemma and (2) nNa~V~s localize to t-tubules ([@B29]; [@B73], [@B72]; [@B138]; [@B93]) (**Figure [1](#F1){ref-type="fig"}**). Indeed, up to 50% of the late I~Na~ in canine cardiac myocytes has been reported to be TTX-sensitive ([@B12]). These results raised the possibility that nNa~V~s, and NCX may constitute essential components of dyadic nanodomains along with LTCCs and RYR2. Since then, multiple groups have provided evidence for co-compartmentation of Na^+^ and Ca^2+^ handling proteins within dyadic nanodomains ([@B104]; [@B54]). In recent years, evidence has mounted that the high gain system of cardiac Ca^2+^ cycling is tightly regulated by nNa~V~s, and NCX localized within the cleft ([@B96]; [@B94], [@B93], [@B95]; [@B129]). However, the molecular stoichiometry of Na^+^/Ca^2+^ handling machinery (NCX, RyR, Na~V~s) and inter-species differences remain to be elucidated.

An additional layer of complexity in dyadic nanodomain function derives from its structure. It encompasses three spatial compartments -- the extracellular space within the t-tubule, the cytosolic subspace, and the terminal cisternae of the junctional SR. In contrast, Na^+^ channel-rich nanodomains at the ID only consist of two compartments, extracellular and intracellular. While much of the inquiry into dyadic nanodomain function has focused on dynamics within the cytosolic subspace, emerging evidence is drawing attention to the complexity of the t-tubular network. Electron microscopy has revealed microfolds along t-tubules ([@B61]), thought to be generated by the action of the protein Bridging integrator 1 (BIN1) ([@B48]; [@B38]). Experimental observations also suggest that diffusion within t-tubules is significantly slowed in comparison to bulk interstitial space ([@B14]; [@B105]; [@B85]; [@B115]). The Lopatin group recently demonstrated that the presence of expansions and constrictions along t-tubules, the result of microfolds, likely accounts for this slow diffusion ([@B120]). This slowed diffusion within t-tubules enables the development of local electrochemical transients within t-tubular nanodomains, paralleling ID nanodomains. This phenomenon has important consequences for cardiac electrophysiology as well as ECC. Likewise local dynamics in luminal Ca^2+^ within the junctional SR would strongly modulate dyadic nanodomain behavior (particularly RYR2 gating) and merit further investigation ([@B45]). While there has been much progress in understanding dyadic nanodomains as the structural and functional units of cardiac ECC, further investigation is needed to understand how structure--function relationships at the nanoscale determine physiology at cellular, tissue, and organ levels.

Pathophysiology
---------------

Dysregulated Ca^2+^ cycling is widely recognized as the cause of arrhythmias in multiple pathological states. Aberrant Ca^2+^ release from the SR can be prompted by SR Ca^2+^ overload, RyR2 dysfunction, or mistimed Ca^2+^ entry across the sarcolemma. This in turn can activate NCX, depolarizing the membrane, and prompting premature beats that can trigger arrhythmias ([@B11]; [@B135]). Intriguingly, a recent report suggests that aberrant cytosolic Ca^2+^ levels may also produce arrhythmogenic conditions by facilitating untimely Na~V~ re-opening ([@B55]). Overall, the behavior of individual Na^+^ and Ca^2+^ -cycling proteins is fairly well-characterized, yet the interplay between Na^+^ and Ca^2+^ within dyadic nanodomains is very much the subject of active inquiry.

Modeling studies suggest that enhanced late Na^+^ entry into dyadic nanodomains can prompt reversal of NCX, resulting in Ca^2+^ entry into the subspace, and thereby, contribute to arrhythmogenic aberrance Ca^2+^ release ([@B6]; [@B96]). Late I~Na~ carried by nNa~V~s has been implicated in inherited arrhythmia disorders such as catecholaminergic polymorphic ventricular tachycardia (CPVT) ([@B93], [@B95]). Specifically, Ca^2+^/calmodulin -- dependent kinase II (CaMKII) -dependent enhancement of nNa~V~ activity during β-adrenergic stimulation contributes to diastolic Ca^2+^ release and consequent arrhythmias *in vivo* via an NCX-mediated mechanism. Additionally, this pro-arrhythmic mechanism was consistent regardless of whether the CPVT resulted from "leaky" RyRs or from SR Ca^2+^ overload. In the broader context, these results point to pathological overload of cytosolic Na^+^ and Ca^2+^ being inextricably linked, particularly within the dyadic subspace.

Consistent with this hypothesis, aberrant Ca^2+^ release is the principal mechanism of arrhythmogenesis in disorders characterized by pathological gain of Na^+^ channel function. Multiple studies have linked pathological enhancement of nNa~V~ function with arrhythmogenic diastolic Ca^2+^ release. These include mice lacking the Na^+^ channel auxiliary subunit β1 (SCN1B) which exhibit enhanced Na~V~1.3 expression ([@B70]), a rat pilocarpine-induced status epilepticus model where Na~V~1.1 expression is elevated ([@B13]), and a murine model of epileptic encephalopathy resulting from a gain of function mutation in Na~V~1.6 ([@B37]). While these cases involve direct enhancement of Na^+^ entry into the dyadic nanodomain via nNa~V~s, LQT3 is characterized by gain of Na~V~1.5 function, resulting in global Na^+^ overload throughout the myocyte. Nonetheless, recent evidence indicates that Na^+^ entry into the dyadic subspace via nNa~V~s is still a key element of arrhythmogenesis in LQT3 ([@B58]). Paralleling the aforementioned results in inherited arrhythmic syndromes, are studies implicating pathological enhancement of late I~Na~ in arrhythmias in acquired forms of ECC dysfunction such as heart failure ([@B124]; [@B121]; [@B122]; [@B107]; [@B5]; [@B75]). Specifically, augmentation of Na^+^ influx via Na~V~1.1 ([@B81]) as well as of NCX function ([@B90]) in failing hearts have been shown to contribute to arrhythmias.

Given that late I~Na~ is central to aberrant Ca^2+^ cycling and arrhythmogenesis in multiple pathologies, it should come as no surprise that late I~Na~ inhibition by drugs such as ranolazine has demonstrated efficacy as an antiarrhythmic therapy ([@B16]). However, emerging research suggests that selective targeting of nNa~V~-mediated Na^+^ entry into dyadic nanodomains may hold even greater promise ([@B93], [@B95]; [@B58]). Additional impetus for pursuing this strategy comes from the dire negative consequences resulting from the off-target effects of non-isoform-selective Na^+^ channel inhibition: although non-selective I~Na~ inhibition suppressed triggered activity following myocardial infarction ([@B117]), the concomitant reduction in excitability precipitated reentrant arrhythmias, thereby increasing mortality ([@B31]; [@B112]). Selective inhibition of nNa~V~ would reduce Na^+^ entry into dyadic nanodomains, thereby ameliorating triggered arrhythmia incidence, without any attendant adverse impact on excitability. Indeed, selective inhibition of nNa~V~s, and of Na~V~1.6 in particular, whether using TTX analogs or a clinically relevant drug, riluzole, has been demonstrated to effectively suppress arrhythmias in murine models of CPVT ([@B93], [@B95]) and LQT3 ([@B94]; [@B58]).

Based on this logic, and available evidence, we posit the following requirements for arrhythmogenesis in pathologies directly driven by Ca^2+^ cycling defects (i.e., CPVT), and those arising from QT prolongation: (1) abnormal RyR2 function, whether genetic or acquired, (2) increased dyadic subspace Ca^2+^ levels, and (3) augmentation of nanodomain Na^+^ entry via nNa~V~s ([@B97], [@B95]; [@B20]; [@B96]; [@B116]). Any individual factor in the absence of the other two is unlikely to cause arrhythmia. For instance, genetic defects in the RyR2 complex alone are insufficient to induce triggered activity ([@B102]; [@B95]); augmentation of Na^+^ entry via nNa~V~, and SR Ca^2+^ load, secondary to β-adrenergic receptor stimulation, is necessary for arrhythmogenesis ([@B95]). On the other hand, LQT may promote CaMKII activity, which in turn modifies the components of the dyadic nanodomain ([@B116]; [@B136]; [@B95]). Given that augmentation of nNa~V~-mediated Na^+^ influx into dyadic nanodomains is a common element of both arrhythmogenic processes, it follows that late I~Na~ inhibition should prove antiarrhythmic in a broad range of pathologies including CPVT ([@B93], [@B95]), LQT3 ([@B58]), LQT type 7 (Andersen-Tawil Syndrome; resulting from loss of repolarization reserve) ([@B94]; [@B53]), and LQT type 8 (Timothy syndrome; resulting from pathological gain of LTCC function) ([@B39]).

While Na~V~ isoform-selectivity is one focus in developing novel antiarrhythmic drugs, we note that the pharmacological mode of action (i.e., use-dependence vs. tonic block) will also determine therapeutic success. Use-dependent Na~V~ inhibitors can effectively ameliorate triggered arrhythmias ([@B117]). However, under conditions such as elevated heart rates, they can suppress excitability and thereby, exacerbate conduction slowing. This, in turn, precipitates reentrant arrhythmias and increases mortality ([@B31]; [@B112]). In contrast, tonic Na~V~ inhibitors function independently of heart rate, thereby avoiding this adverse effect. Therefore, we postulate that tonic blockade may hold greater potential for delivering efficacy with safety. Intriguingly, a recent report by [@B17] provides clues to fundamental properties (inhibitor protonation state determines binding site) that may lead to development of novel Na~V~ blockers with tailored modes of action. This highlights the need for mechanistically-driven drug development research grounded in understanding of atomic level Na~V~ structure.

As with ID nanodomains, the behavior of dyadic nanodomains is determined not only by the function of their Na^+^/Ca^2+^ cycling protein constituents but also by their local ultrastructure. An example of this is found in failing hearts where β-adrenergic stimulation fails to effectively enhance ECC, despite augmented nNa~V~ and NCX function ([@B137]). This is likely a result of t-tubules being severely disrupted in failing hearts ([@B66]), compromising cell-wide coordination of individual nanodomains. In addition, the remaining t-tubules in these hearts contain abnormal dyadic nanodomains consisting of nNa~V~s, NCX, and hypersensitized RyRs which are prone to arrhythmogenic aberrant Ca^2+^ release ([@B10]). Additionally, loss of BIN1 has been linked to compromised LTCC trafficking as well as loss of t-tubule microfolds in heart failure ([@B18]; [@B48]; [@B60]). Both experimental and modeling studies suggest that the latter effect could compromise the previously discussed slowing of diffusion within t-tubules, thereby dysregulating electrophysiology and ECC. Indeed, the Sachse and Bridge groups have demonstrated that the arrhythmia burden in failing hearts is reduced secondary to restoration of the t-tubule network following cardiac resynchronization therapy ([@B103]; [@B67]; [@B66]). Thus, available evidence points to dyadic nanodomains as promising targets for the prevention of arrhythmias resulting from aberrant Ca^2+^ cycling.

Conclusion
==========

Current research, propelled by emerging technologies capable of assessing structure/function at the nanoscale, suggests that nanodomains located at the ID and the t-tubule may respectively constitute the functional units of cardiac electrical excitation and ECC. Thus, we are beginning to appreciate nanodomain dysfunction, i.e., nanopathy, as a key mechanistic driver of cardiac disease and arrhythmogenesis. It follows therefore that antiarrhythmic treatments should be designed to correct underlying nanopathies, and indeed, such therapies currently under investigation show a great deal of promise. In the broader context, the emerging understanding of how nanoscale biophysics and biochemistry determine cardiovascular physiology and pathophysiology across protein, cell, tissue, and organ scales may represent a paradigm shift on par with the advent of molecular biology. It should drive multiple avenues of scientific and medical research including (1) new diagnostic approaches that can non-invasively interrogate functional nanodomains within patients, (2) new methods to assess nanodomain alterations during autopsies, and (3) new therapeutic approaches designed to restore nanodomain structure/function.
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